SecBot SecBot

VVOS

Vivos Therapeutics, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001716166 Biotech & Drug Discovery
$0.1250 −0.01 (−4.58%)
Oct 27 4:00 PM ET · prev $0.1310
Market cap
$4.5M
Nano cap
Median target
$2.50
+1900% · range $0.7500–3.10
Next earnings
Nov 17
in 21 days · EPS est. −$0.30
1 year
−95.4%
from $2.72 · Oct 27
30 days
−6.7%
from $0.1340
52-week range
$0.1250–2.72
at the low
Avg volume 20D
8.22M
Oct 20 spike 76.70M
Short interest
🔒 Subscribers only
Insider net
+$10.4M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 2 bearish · 2 bullish · 3 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/11 ·Next Earnings date, Nov 17, 2026
Strongest MIXED Vivos Therapeutics closed its acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $10.4M at an average $0.9558. No open-market sales. Price is 87% below their cost.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 0 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.253 → −$0.302 over 90 days.

  • TrendDOWNTREND

    29% below its 50-day average. New closing low $0.1250 on Oct 27.

  • SocialQUIET

    No Reddit mentions this week. Last mention Sep 30.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED39,154$17.8K
NORTHERN TRUST CORPADD20,775$9.4K
GEODE CAPITAL MANAGEMENT, LLCADD95,543$112.7K
VANGUARD GROUP INCDOUBLED304,161$617.4K
UBS Group AGDOUBLED12,677$25.7K
OSAIC HOLDINGS, INC.NEAR_EXIT1,143$2.3K
MORGAN STANLEYNEAR_EXIT7$14.00
VANGUARD GROUP INCDOUBLED91,461$283.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +1900%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jun 4, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Reddit
Recent posts
r/pennystocks Neutral 28d ago
Anyone else keeping an eye on these micro-cap charts? Sorting out my watchlists.
1 upvotes · 5 comments
All social signals and their track records

Insider ledger

Form 4
$10.4M
bought · 1 insider
$0
sold · 0 insiders
−86.9%
vs their $0.9558 cost
DateInsiderTypeValue
Sep 14, 2026🔒 Fresh data, subscribers onlyAWARD
Sep 14, 2026🔒 Fresh data, subscribers onlyAWARD
Sep 14, 2026
JOHNSON GREGG C
Director
AWARD12,000 sh
Sep 14, 2026
SOKOLOW LEONARD J
Director
AWARD12,000 sh
Jul 31, 2026
Amman Bradford K.
Principal Accounting Officer
AWARD$61.5K
Jul 31, 2026
Amman Bradford K.
Principal Accounting Officer
AWARD$102.5K
Jun 30, 2026
Huntsman Ronald Kirk
Chief Executive Officer
OTHER$50.0K
Jun 30, 2026
Huntsman Ronald Kirk
Chief Executive Officer
OTHER$50.0K

Earnings setup

Estimates
Nov 17
reports in 21 days
−$0.30
EPS estimate, this quarter
−19%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.30-$0.54–-$0.12+0.0%$5.5M
Next Q-$0.25-$0.52–-$0.07+0.0%$6.0M
Current FY-$1.34-$2.14–-$0.75+3.6%$21.8M
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

9 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Vivos Therapeutics received a letter from Nasdaq on October 20, 2026 confirming compliance with the minimum…
8-K — Impact 4/10
Oct 19, 2026 Press
Vivos Therapeutics closed its acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in…
Impact 6/10
Oct 19, 2026 M&A
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic A
Oct 19, 2026 SEC
Vivos Therapeutics closed the acquisition of an 11% equity stake in SOD Sciences and a 50% co-ownership interest in…
8-K — Impact 6/10
Oct 15, 2026 SEC
Vivos Therapeutics entered into a definitive agreement to acquire an 11% fully diluted equity stake in SOD Sciences…
8-K — Impact 6/10
Oct 15, 2026 Press
Vivos Therapeutics issued 12,000 shares of Series C Convertible Preferred Stock (stated value $12M) to acquire an 11%…
Impact 5/10
Sep 14, 2026 Insider
🔒 Fresh data, subscribers only
Sep 14, 2026 Insider
🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
VVOS Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Oct 19, 2026
M&A
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and…
Oct 15, 2026
M&A
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Transaction Expected to Increase Stockholders’ Equity; Opens Potential Collaboration Opportunities From New Strategic Alliances...
Sep 30, 2026
Short interest
Short Interest: VVOS up 76% to 2.9M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈8.52% of shares outstanding (est.)
Sep 29, 2026
Press release
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Management is Executing on Plan to Immediately Reduce Overhead by an Estimated $3.6 million Annually While Also Driving Top-Line Revenue Vivos…
Sep 15, 2026
Short interest
Short Interest: VVOS down 35% to 1.6M shares
Settlement 2026-09-15 | Days to cover: 1.00 | ≈8.08% of shares outstanding (est.)

SecBot reports

15 filings · 4 press releases · 2 bullish · 6 bearish · 4 mixed · 3 neutral
All VVOS filing & press-release reports (19)